



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/380,447	09/01/1999	Sachdev S. Sidhu	11669.141USWO	2633
23552	7590	08/30/2007	EXAMINER	
MERCHANT & GOULD PC			STEELE, AMBER D	
P.O. BOX 2903				
MINNEAPOLIS, MN 55402-0903			ART UNIT	PAPER NUMBER
			1639	
			MAIL DATE	DELIVERY MODE
			08/30/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO. 09380447	FILING DATE 9/1/1999	FIRST NAMED INVENTOR SIDHU ET AL.	ATTORNEY DOCKET NO. 11669.141USWO
------------------------------------	--------------------------------	---	---

EXAMINER

Amber D. Steele

ART UNIT

PAPER

1639

20070821

DATE MAILED:


Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

- 1)The present application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821 (a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825. The sequence listing has various errors as indicated in the attached Raw Sequence Listing and error report.
- 2)Applicant is given ONE MONTH from the date of this letter within which to comply with the Sequence Rules, 37 CFR 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In NO case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.
- 3)Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amber D. Steele whose telephone number is 571-272-5538. The examiner can normally be reached Monday through Friday 9:00AM-5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Doug Schultz can be reached at 571-272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ADS

August 21, 2007


MARK L. SHIBUYA
PRIMARY EXAMINER

Notice to Comply	Application No. 09/380,447	Applicant(s) S IDHU ET AL.
	Examiner Steele, A. D.	Art Unit 1639
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES		
<p>Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).</p> <p>The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):</p> <ul style="list-style-type: none"> <input checked="" type="checkbox"/> 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). <input type="checkbox"/> 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). <input type="checkbox"/> 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). <input checked="" type="checkbox"/> 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." <input type="checkbox"/> 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). <input type="checkbox"/> 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). <input checked="" type="checkbox"/> 7. Other: see attached PTO-90C. <p>Applicant Must Provide:</p> <ul style="list-style-type: none"> <input checked="" type="checkbox"/> An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". <input checked="" type="checkbox"/> An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. <input checked="" type="checkbox"/> A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). <p>For questions regarding compliance to these requirements, please contact:</p> <p>For Rules Interpretation, call (571) 272-2510 For CRF Submission Help, call (571) 272-2501/2583. PatentIn Software Program Support Technical Assistance.....703-287-0200 To Purchase PatentIn Software.....703-306-2600</p> <p>PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY</p>		

=====

Sequence Listing could not be accepted due to errors.
See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: Mon Jul 30 14:06:26 EDT 2007

=====

Reviewer Comments:

<150> US 60/134,870

<151> 1999 05 19

<150> US 60/133,296

<151> 1999 05 10

<150> US 60/103,514

<151> 1998 10 08

<150> US 60/094,291

<151> 1998 07 27

<150> PCT/USUS99/16596

<151> 1999 07 22

The above non-ASCII characters ("squares") between dates appear throughout the submitted sequence listing file; they also appear in <222> responses which indicate locations within the sequence. Please replace them with hyphens.

<400> 293

His His His His

1

69

Please remove the above "69" appearing at the end of the submitted file.

Application No: 09380447

Version No: 3.0

Input Set:**Output Set:**

Started: 2007-07-19 18:29:54.051
Finished: 2007-07-19 18:31:26.799
Elapsed: 0 hr(s) 1 min(s) 32 sec(s) 748 ms
Total Warnings: 284
Total Errors: 366
No. of SeqIDs Defined: 292
Actual SeqID Count: 293

Error code	Error Description		
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <141>		
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <151>		
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <151>		
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <151>		
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <151>		
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <151>		
E 287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <151>		
W 213	Artificial or Unknown found in <213> in SEQ ID (1)		
E 341	'Xaa' position not defined	SEQID (1)	POS (12)
E 341	'Xaa' position not defined	SEQID (1)	POS (13)
E 341	'Xaa' position not defined	SEQID (1)	POS (14)
E 341	'Xaa' position not defined	SEQID (1)	POS (15)
E 341	'Xaa' position not defined	SEQID (1)	POS (16)
E 341	'Xaa' position not defined	SEQID (1)	POS (17)
E 341	'Xaa' position not defined	SEQID (1)	POS (18)
E 341	'Xaa' position not defined	SEQID (1)	POS (19)
E 341	'Xaa' position not defined	SEQID (1)	POS (20)
E 341	'Xaa' position not defined	SEQID (1)	POS (21)
E 341	'Xaa' position not defined	SEQID (1)	POS (22)
E 341	'Xaa' position not defined	SEQID (1)	POS (23)
E 341	'Xaa' position not defined	SEQID (1)	POS (24)

Input Set:

Output Set:

Started: 2007-07-19 18:29:54.051
Finished: 2007-07-19 18:31:26.799
Elapsed: 0 hr(s) 1 min(s) 32 sec(s) 748 ms
Total Warnings: 284
Total Errors: 366
No. of SeqIDs Defined: 292
Actual SeqID Count: 293

Error code	Error Description
E 341	'Xaa' position not defined SEQID (1) POS (25)
E 341	'Xaa' position not defined SEQID (1) POS (26)
E 341	'Xaa' position not defined SEQID (1) POS (27)
E 341	'Xaa' position not defined SEQID (1) POS (28)
E 341	'Xaa' position not defined SEQID (1) POS (29)
E 341	'Xaa' position not defined SEQID (1) POS (30)
E 257	Invalid sequence data feature in <221> in SEQ ID (2)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
E 257	Invalid sequence data feature in <221> in SEQ ID (5)
E 257	Invalid sequence data feature in <221> in SEQ ID (6)
E 257	Invalid sequence data feature in <221> in SEQ ID (7)
E 257	Invalid sequence data feature in <221> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)

Input Set:

Output Set:

Started: 2007-07-19 18:29:54.051
Finished: 2007-07-19 18:31:26.799
Elapsed: 0 hr(s) 1 min(s) 32 sec(s) 748 ms
Total Warnings: 284
Total Errors: 366
No. of SeqIDs Defined: 292
Actual SeqID Count: 293

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20)
W 213	Artificial or Unknown found in <213> in SEQ ID (21)
E 342	'n' position not defined found at POS: 20 SEQID(21)
E 342	'n' position not defined found at POS: 22 SEQID(21)
E 342	'n' position not defined found at POS: 26 SEQID(21)
E 342	'n' position not defined found at POS: 28 SEQID(21)
E 342	'n' position not defined found at POS: 31 SEQID(21)
E 342	'n' position not defined found at POS: 34 SEQID(21)
E 342	'n' position not defined found at POS: 38 SEQID(21)
E 342	'n' position not defined found at POS: 41 SEQID(21)
E 342	'n' position not defined found at POS: 44 SEQID(21)
E 342	'n' position not defined found at POS: 47 SEQID(21)
W 213	Artificial or Unknown found in <213> in SEQ ID (22)
E 342	'n' position not defined found at POS: 19 SEQID(22)
E 342	'n' position not defined found at POS: 22 SEQID(22)
E 342	'n' position not defined found at POS: 26 SEQID(22)
E 342	'n' position not defined found at POS: 28 SEQID(22)
E 342	'n' position not defined found at POS: 31 SEQID(22)
E 342	'n' position not defined found at POS: 35 SEQID(22)
E 342	'n' position not defined found at POS: 38 SEQID(22)

Input Set:

Output Set:

Started: 2007-07-19 18:29:54.051
Finished: 2007-07-19 18:31:26.799
Elapsed: 0 hr(s) 1 min(s) 32 sec(s) 748 ms
Total Warnings: 284
Total Errors: 366
No. of SeqIDs Defined: 292
Actual SeqID Count: 293

Error code	Error Description
E 342	'n' position not defined found at POS: 41 SEQID(22)
E 342	'n' position not defined found at POS: 44 SEQID(22)
E 342	'n' position not defined found at POS: 46 SEQID(22) This error has occurred more than 20 times, will not be displayed
W 213	Artificial or Unknown found in <213> in SEQ ID (23)
W 213	Artificial or Unknown found in <213> in SEQ ID (24)
W 213	Artificial or Unknown found in <213> in SEQ ID (25)
W 213	Artificial or Unknown found in <213> in SEQ ID (26)
W 213	Artificial or Unknown found in <213> in SEQ ID (27) This error has occurred more than 20 times, will not be displayed
E 257	Invalid sequence data feature in <221> in SEQ ID (36)
E 257	Invalid sequence data feature in <221> in SEQ ID (56)
E 355	Empty lines found between the amino acid numbering and the
E 321	No. of Bases conflict, this line has no nucleotides SEQID (293)
E 252	Calc# of Seq. differs from actual; 292 seqIDs defined; count=293

Sequence Listing

<110> Sidhu, Sachdev S.
Weiss, Gregory A.
Wells, James A.

<120> TRANSFORMATION EFFICIENCY IN PHAGE DISPLAY THROUGH MODIFICATION OF A
COAT PROTEIN

<130> 11669.141USWO

<140> 09380447
<141> 1999-09-01

<150> US 09/380,447
<151> 1999 09 01

<150> US 60/134,870
<151> 1999 05 19

<150> US 60/133,296
<151> 1999 05 10

<150> US 60/103,514
<151> 1998 10 08

<150> US 60/094,291
<151> 1998 07 27

<150> PCT/USUS99/16596
<151> 1999 07 22

<160> 292

<210> 1
<211> 50
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic coat protein

<220>
<221> unsure
<222> 12 30
<223> unknown amino acid

<400> 1
Met Ser Lys Ser Thr Phe Lys Lys Phe Leu Lys Xaa Xaa Xaa Xaa
1 5 10 15

Xaa
20 25 30

Glu Thr Ala Ser Ala Gln Leu Ser Asn Phe Ala Ala Lys Ala Pro
35 40 45

Asp Asp Gly Glu Ala

50

<210> 2

<211> 50

<212> PRT

<213> M13 phage

<220>

<221> M13 phage

<222> 1 50

<223> coat protein VIII

<400> 2

Ala Glu Gly Asp Asp Pro Ala Lys Ala Ala Phe Asn Ser Leu Gln
1 5 10 15

Ala Ser Ala Thr Glu Tyr Ile Gly Tyr Ala Trp Ala Met Val Val
20 25 30

Val Ile Val Gly Ala Thr Ile Gly Ile Lys Leu Phe Lys Lys Phe
35 40 45

Thr Ser Lys Ala Ser
50

<210> 3

<211> 50

<212> PRT

<213> f1 phage

<220>

<221> f1 phage

<222> 1 50

<223> coat protein VIII

<400> 3

Ala Glu Gly Asp Asp Pro Ala Lys Ala Ala Phe Asp Ser Leu Gln
1 5 10 15

Ala Ser Ala Thr Glu Tyr Ile Gly Tyr Ala Trp Ala Met Val Val
20 25 30

Val Ile Val Gly Ala Thr Ile Gly Ile Lys Leu Phe Lys Lys Phe
35 40 45

Thr Ser Lys Ala Ser
50

<210> 4

<211> 50

<212> PRT

<213> fd phage

<220>

<221> fd phage

<222> 1 50

<223> coat protein VIII

<400> 4

Ala Glu Gly Asp Asp Pro Ala Lys Ala Ala Phe Asp Ser Leu Gln
1 5 10 15

Ala Ser Ala Thr Glu Tyr Ile Gly Tyr Ala Trp Ala Met Val Val
20 25 30

Val Ile Val Gly Ala Thr Ile Gly Ile Lys Leu Phe Lys Lys Phe
35 40 45

Thr Ser Lys Ala Ser

50

<210> 5

<211> 50

<212> PRT

<213> Zj 2 phage

<220>

<221> Zj 2 phage

<222> 1 50

<223> coat protein VIII

<400> 5

Ala Glu Gly Asp Asp Pro Ala Lys Ala Ala Phe Asp Ser Leu Gln
1 5 10 15

Ala Ser Ala Thr Glu Tyr Ile Gly Tyr Ala Trp Ala Met Val Val
20 25 30

Val Ile Val Gly Ala Thr Ile Gly Ile Lys Leu Phe Lys Lys Phe
35 40 45

Ala Ser Lys Ala Ser

50

<210> 6

<211> 50

<212> PRT

<213> Ifl phage

<220>

<221> Ifl phage

<222> 1 50

<223> coat protein VIII

<400> 6

Asp Asp Ala Thr Ser Gln Ala Lys Ala Ala Phe Asp Ser Leu Thr
1 5 10 15

Ala Gln Ala Thr Glu Met Ser Gly Tyr Ala Trp Ala Leu Val Val
20 25 30

Leu Val Val Gly Ala Thr Val Gly Ile Lys Leu Phe Lys Lys Phe
35 40 45

Val Ser Arg Ala Ser
50

<210> 7
<211> 50
<212> PRT
<213> I2 2 phage

<220>
<221> I2 2 phage
<222> 1 50
<223> coat protein VIII

<400> 7
Ser Thr Ala Thr Ser Tyr Ala Thr Glu Ala Met Asn Ser Leu Lys
1 5 10 15

Thr Gln Ala Thr Asp Leu Ile Asp Gln Thr Trp Pro Val Val Thr
20 25 30

Ser Val Ala Val Ala Gly Leu Ala Ile Arg Leu Phe Lys Lys Phe
35 40 45

Ser Ser Lys Ala Val
50

<210> 8
<211> 50
<212> PRT
<213> Ike phage

<220>
<221> Ike phage
<222> 1 50
<223> coat protein VIII

<400> 8
Asn Ala Ala Thr Asn Tyr Ala Thr Glu Ala Met Asp Ser Leu Lys
1 5 10 15

Thr Gln Ala Ile Asp Leu Ile Ser Gln Thr Trp Pro Val Val Thr
20 25 30

Thr Val Val Val Ala Gly Leu Val Ile Arg Leu Phe Lys Lys Phe
35 40 45

Ser Ser Lys Ala Val
50

<210> 9
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> oligonucleotide primer

<400> 9
aaaagaattc ccgacaccat cgaatggtgc 30

<210> 10
<211> 35
<212> DNA
<213> Artificial sequence

<220>
<223> oligonucleotide primer

<400> 10
accagatgca taagccgagg cgaaaaacat catcg 35

<210> 11
<211> 56
<212> DNA,
<213> Artificial sequence

<220>
<223> oligonucleotide primer

<400> 11
ttttctagac aggcctccca ccagatgcat aagccgaggc ggaaaaacatc 50
atcgta 56

<210> 12
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> oligonucleotide primer

<400> 12
gctatcgaa tgcatacgccc atcacccggca cctcg 34

<210> 13
<211> 61
<212> DNA
<213> Artificial sequence

<220>
<223> oligonucleotide primer

<400> 13
gagtcatagt cgtcaggcgc ctccctccgga tcctccaccc accttggta 50
agggtgtcggtg g 61

<210> 14

<211> 18
<212> DNA
<213> Artificial sequence

<220>

<223> oligonucleotide primer

<400> 14
gggtatcttag aggttgag 18

<210> 15
<211> 46
<212> DNA
<213> Artificial sequence

<220>

<223> oligonucleotide primer

<400> 15
tggagctccc ggatcctcca ccgctctgga agccacagct gccctc 46

<210> 16
<211> 42
<212> DNA
<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 16
ggatccggga gctccagctg atgaggtgac gatcccgcaa aa 42

<210> 17
<211> 42
<212> DNA
<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 17
gatcccgcaa aagcggcctg atgatccctg caagcctcag cg 42

<210> 18
<211> 42
<212> DNA
<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 18
caaggctcag cgaccgaatg atgaggttat gcgtgggcga tg 42

<210> 19
<211> 42

<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 19
cgctggcga tggttgttg atgagtcggc gcaactatcg gt 42

<210> 20
<211> 42
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 20
gcaactatcg gatatcaagtg atgaaagaaa ttcacacctga aa 42

<210> 21
<211> 66
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<220>
<221> unsure
<222> 20, 22, 26, 28, 31, 34, 38, 41, 44, 47
<223> unknown base

<400> 21
ggatccggga gctccagcrn tnasrntnas nasnycrntr narntnrtt 50

taactccctg caagcc 66

<210> 22
<211> 66
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<220>
<221> unsure
<222> 19, 22, 26, 28, 31, 35, 38, 41, 44, 46
<223> unknown base

<400> 22
gatcccgcaa aagcggccnw tnasrntnyt nasrntrntr ntrntnasta 50

tatcggttat gcgtgg 66

<210> 23
<211> 70
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<220>
<221> unsure
<222> 19, 22, 25, 28, 31, 35, 38, 41, 44, 47
<223> unknown base

<400> 23
caagcctcag cgaccgaanw cnwcnktnwc nyytnkgnyt nkgnwttnwtg 50

tcattgtcgg cgcaactatc 70

<210> 24
<211> 66
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<220>
<221> unsure
<222> 19, 22, 25, 28, 31, 34, 37 38, 40 41, 43 44
<223> unknown base

<400> 24
gcgtgggcga tggttgttnw tnwcnwtnkt nytnytnnnt nnntaaagct 50

gtttaagaaa ttcacc 66

<210> 25
<211> 72
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<220>
<221> unsure
<222> 19 20, 22 23, 31 32, 34 35, 37 38, 43 44, 46 47
<223> unknown base

<400> 25
gcaactatcg gtatcaagnn gnnsaagaaa nnnsnnngna aanngnnngtg 50

ataaaccgat acaattaaag gc 72

<210> 26
<211> 66
<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 26

gatcccccaa aaggcccta tgaggcttt gaggatattt ctactaacta 50

tatcggttat gcgtgg 66

<210> 27

<211> 36

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 27

ccgacaccct ccaatgctga ggaaacacaa cagaaa 36

<210> 28

<211> 36

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 28

ttcaggaagg acatggctaa ggtcgagaca ttccctg 36

<210> 29

<211> 75

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 29

aactacgggc tgctcgcttg cttcaggaag gacatggaca aggtcgagac 50

atccctggct atcgtgcagt gccgc 75

<210> 30

<211> 57

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 30

ttcaggaagg acatggacgc tgcgagaca ttccctggcta tcgtccagtg 50

ccgtct 57

<210> 31

<211> 42

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 31

ggtggaggat ccgggagctg atgagccgag ggtgacgatc cc 42

<210> 32

<211> 46

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 32

caccaaggtg gtcttagatc aataataagc cgagggtgac gatccc 46

<210> 33

<211> 50

<212> PRT

<213> Artificial sequence

<220>

<223> P12 1 variant

<400> 33

Met Ser Lys Ser Thr Phe Lys Lys Phe Leu Lys Val Phe Val Phe

1

5

10

15

Ser Val Asp Val Asp Asn Asn Trp Ile Trp Ala Val Gly Ile Ile

20

25

30

Tyr Met Leu Leu Val Glu Ala Ser Pro Trp Ala Ala Lys Ala Pro

35

40

45

Asp Asp Gly Glu Ala

50

<210> 34

<211> 93

<212> DNA

<213> Artificial sequence

<220>

<223> oligonucleotide linker library

<400> 34

gagggcagct gtggcttcgg tggcggtvvc vvcvvvcvvvc vcvvvcvvvcv 50

cvvcvvvcvvc vvcvvvcvvvc gcggtgccga gggtgacgat ccc 93

<210> 35
<211> 51
<212> DNA
<213> Artificial sequence

<220>
<223> oligonucleotide linker library

<400> 35

caccaaggtg gtctagagvv cvvcvvvcvvc vvcggcagg gtagacgatcc 50

c 51

<210> 36
<211> 67
<212> DNA
<213> Artificial sequence

<220>
<221> Artificial sequence
<222> 1 67
<223> oligonucleotide linker library

<400> 36

caccaaggtg gtctagagcv vcvvvcvvvcv cvvcvvvcvvc vvcvvvcvv 50

ccgagggtga cgatccc 67

<210> 37
<211> 82
<212> DNA
<213> Artificial sequence

<220>
<223> oligonucleotide linker library

<400> 37

caccaaggtg gtctagagcv vcvvvcvvvcv cvvcvvvcvvc vvcvvvcvv 50

vcvvvcvvvcv cvvcggcag ggtgacgatc cc 82

<210> 38
<211> 97
<212> DNA
<213> Artificial sequence

<220>
<223> oligonucleotide linker library

<400> 38

caccaaggtg gtctagagcv vcvvvcvvvcv cvvcvvvcvvc vvcvvvcvv 50

vcvvvcvvvcv cvvcvvvcvvc vvcvvvcvv 97

<210> 39

<211> 112
<212> DNA
<213> Artificial sequence

<220>
<223> oligonucleotide linker library

<400> 39
caccaagggtg gtctagagcv vcvvcvvvcv cvvcvvvcv vvcvvvcv 50

vcvvvcvvvcv cvvcvvvcv vvcvvvcv vcvvcvvvcv cvvcgccgag 100

ggtgacgatc cc 112

<210> 40
<211> 66
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 40
aagttcgcta gagatgctta tgaggctt gaggatattg ctactaacta 50

tatcggttat gcgtgg 66

<210> 41
<211> 66
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 41
gaggatattg ctactaacct tttctttctc cttggactg tgcatttgt 50

cattgtcgcc gcaact 66

<210> 42
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 42
gaaaaagcgg cctataacgc tcttgaggat att 33

<210> 43
<211> 33
<212> DNA
<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 43

 tatgaggctc ttgaggccat tgctactaac tat 33

<210> 44

<211> 33

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 44

 gaggctcttg aggattcagc tactaactat atc 33

<210> 45

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 45

 gatcccccaa aagccgccta tgaggctttt gaggatattt ctactaacta 50

 tatcggttat gcgtgg 66

<210> 46

<211> 66

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 46

 gagggcagct gtggcttcca gagcggtggaa ggatccggga gctccagcgc 50

 cgagggtgac gatccc 66

<210> 47

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 47

 cccgcaaaaag cggcctttaa cgctctgcaa gccattgcga ccgaatatata 50

 cggttatgcg 60

<210> 48

<211> 66

<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 48
caaggctcag cgaccgaact ttttttctc cttgggactg tgcatcttgt 50

cattgtcgcc gcaact 66

<210> 49
<211> 33

<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 49
tccggggact ccagcgccaa gagtgagaag ttc 33

<210> 50
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 50
gggagctcca gcgatgagag tgagaagtgc 33

<210> 51
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 51
agctccagcg ataagggtga gaagttcgct aga 33

<210> 52
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 52
tccagcgata agagtgacaa gttcgctaga gat 33

<210> 53

<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 53
agcgataaga gtgaggattt cgcttagagat gct 33

<210> 54
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 54
gataagagtg agaagccgc tagagatgt ttt 33

<210> 55
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 55
agtgagaagt tcgctaaaga tgctttAAC tcc 33

<210> 56
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<221> Artificial sequence
<222> 1 33
<223> mutagenic oligonucleotide

<400> 56
gagaagttcg ctagagcggc tttaactcc ctg 33

<210> 57
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 57
cccgcaaaag cggcTTGA ggctcttgag gat 33

<210> 58

<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 58
gcaaaaagcggt cctataaacgt ctcttgaggat tatt 34

<210> 59
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 59
aaagcggccat atgagtccct tgaggatatt gct 33

<210> 60
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 60
gccttatgagg ctcttcaaga tattgtactt aac 33

<210> 61
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 61
tatgaggctc ttgaggccat tgctactaac tat 33

<210> 62
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 62
gaggctttg aggattcagc tactaactat atc 33

<210> 63
<211> 33

<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 63
gaggatattg ctactgaata tatcggttat gcg 33

<210> 64
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 64
gcctcagcga ccgaatattt ctttctcctt ggg 33

<210> 65
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 65
tcagcgaccg aacttatctt tctccttggg act .33

<210> 66
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 66
gcgaccgaac ttttcggtct ctttggact gtg 33

<210> 67
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 67
accgaacttt tcttttatct tgggactgtg cat 33

<210> 68
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 68
qaactttct ttctcaccaqq qactgtqcat ctt 33

<210> 69
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 69
cttttcttc tcctttggac tqtgcatctt qtc 33

<210> 70
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 70
ttctttctcc ttqqqqcqqt qcataatgttc att 33

<210> 71
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 71
tttctcccttg ggactatgca tcttgtcatt gtc 33

<210> 72
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> mutagenic oligonucleotide

<400> 72
ctccttggga ctgtggttct tgtcattgtc ggc 33

<210> 73
<211> 33
<212> DNA
<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 73

cttgggactg tgcgttgtt cattgtcgac gca 33

<210> 74

<211> 36

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 74

gcaaaaagcgg cctataactc ctttgaggat attgtc 36

<210> 75

<211> 48

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 75

gcaaaaagcgg cctataacgc ttgttggaggat tcagctacta actatatac 48

<210> 76

<211> 60

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 76

cccgcaaaag cggcctatga gtccttgag gattcagcta ctaactatac 50

cggtttatgcg 60

<210> 77

<211> 48

<212> DNA

<213> Artificial sequence

<220>

<223> mutagenic oligonucleotide

<400> 77

gcaaaaagcgg cctataactc ctttgaggat tcagctacta actatatac 48

<210> 78

<211> 10

<212> PRT

<213> Artificial sequence

<220>

<223> peptide linker

<40